[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"uti---urinary-tract-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:uti---urinary-tract-infection":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,54,82],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":33,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100634157","potential-of-interface-care-models-to-deliver-more-appropriate-care-to-patients-with-acute-medical-illness-100634157",false,"NCT07536035","Potential of Interface Care Models to Deliver More Appropriate Care to Patients With Acute Medical Illness","Potential of Interface Care Models to Deliver More Appropriate Care to Patients With Acute Medical Illness in Singapore and Decrease Utilisation of Acute Care Bed-days","Inclusion Criteria:\n\n* AMU inclusion criteria - admission from ED to AMU directly\n* Control group inclusion criteria - admission from ED to GW directly\n* Acute medical illnesses that includes infection-related conditions, falls-disequilibrium, and acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD).\n\nExclusion Criteria:\n\n* Below 21 years old\n* Patients undergoing active chemotherapy\n* Patients with active pregnancy\n* Patients admitted less than 24 hours\n* Cerebrovascular disease requiring thrombolysis or intravascular intervention","ALL","21 Years",{"count":19,"type":20},220,"ESTIMATED","OBSERVATIONAL","Every country in the world is experiencing growth in both the size and the proportion of older persons. As a result of the changes, the profile and needs of people with medical illnesses have evolved. How care is delivered to patients has to keep pace with these changes, or patients will experience poor care at high cost and not have their needs met. A new model of care has emerged to meet these challenges: Acute Medical Unit. Despite considerable investment and popularity of this model, questions remain: (i) Who benefits most from this care model? (ii) How may these models be most effectively implemented for the best results? (iii) How effective are these models? Singapore is well-placed to answer these questions with its national healthcare system and excellent research institutions. The investigators plan to study how effective the model is by comparing patients with similar profiles exposed to both these care models compared to how hospital care is usually provided, looking for four differences: (i) how long patients stay in hospital, (ii) how often they use the emergency department (iii) quality of health (iv) cost. Additionally, the investigators seek to characterise patterns of health needs for this group of patients.",[24,25,26,27,28,29,30,31,32],"Falls Injury","Falls","Hospitalization in Acute Care","Chronic Obstructive Pulmonary Disease (COPD)","Infection","Acute Exacerbation of Asthma","Pneumonia","UTI - Urinary Tract Infection","URTI - Viral Upper Respiratory Tract Infection",[34,35,36,37,38,39,40],"Acute Medical Unit","Acute Medicine","Interface Care","Clinical effectiveness","Cost effectiveness","prospective observational","matched controlled","RECRUITING","2026-04-10",{"date":44,"type":45},"2026-04-17","ACTUAL",{"date":47,"type":45},"2024-09-30",{"date":49,"type":20},"2026-05-31",{"name":51,"class":52},"National University Hospital, Singapore","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":4,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":53},"100608536","urine-alkalinization-for-uti-in-women-rct-100608536","NCT07202832","Urine Alkalinization for UTI in Women: RCT","Efficacy and Safety of Urine Alkalinization in Treatment of Uncomplicated Urinary Tract Infection in Women: A Randomized Controlled Trial","UTI","Inclusion Criteria:\n\n* Women aged ≥ 18 and ≤ 50.\n* Symptoms of uncomplicated UTI or cystitis; including urinary frequency, urgency and dysuria.\n* Positive urine culture of mid-urine urine.\n\nExclusion Criteria:\n\n* Post menopausal women.\n* Pregnancy.\n* Complicated UTIs, such as those requiring hospital admission, infections associated with fevers, those with urinary tract abnormalities, urinary tract calculi or urinary tract obstruction.\n* History of recurrent UTI.\n* Recent antibiotic use.\n* Acute pyelonephritis.\n* Immunocompromising conditions.\n* Chronic conditions such as interstitial cystitis, painful bladder syndrome, chronic pelvic pain syndrome.\n* Patients with CKD.\n* Patients with allergy to potassium citrate.","FEMALE","18 Years","50 Years",{"count":66,"type":20},50,"INTERVENTIONAL",[69],"NA","The goal of this clinical trial is to evaluate whether urinary alkalinization using potassium citrate can relieve symptoms and improve urine culture results in women aged 18 to 50 years with uncomplicated urinary tract infections (UTIs). The main questions it aims to answer are:\n\nDoes urinary alkalinization reduce UTI symptom scores by Day 7?\n\nDoes it lead to better urine culture results compared to antibiotic?\n\nResearchers will compare urinary alkalinization with potassium citrate to antibiotic to see if it provides more symptom relief and better microbiological outcomes.\n\nParticipants will:\n\nTake either potassium citrate or antibiotic\n\nBe assessed for symptoms and adverse events on Day 7\n\nProvide a urine sample for culture before and after treatment\n\nReport any return visits due to worsening symptoms or medication side effects",[31],"NOT_YET_RECRUITING","2025-09-24",{"date":75,"type":45},"2025-10-02",{"date":77,"type":20},"2025-10-15",{"date":79,"type":20},"2027-01-01",{"name":81,"class":52},"Assiut University",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":62,"minAge":90,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":67,"phases":94,"briefSummary":95,"conditions":96,"keywords":104,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":53},"100588378","a-trial-of-d-mannose-for-the-prophylaxis-of-recurrent-urinary-tract-infections-100588378","NCT06940622","A Trial of D-mannose for the Prophylaxis of Recurrent Urinary Tract Infections","A Randomized Controlled Trial of D-mannose for the Prophylaxis of Recurrent Urinary Tract Infections in Post-menopausal Women","DmannoseRCT","Inclusion Criteria:\n\n* Female, post-menopausal, age ≥ 55 years old\n* Diagnosis of recurrent UTI, defined as ≥ 3 symptomatic culture-proven UTI episodes in 12 months or ≥ 2 in 6 months.\n* Currently free from a UTI determined based on absence of symptoms as determined by the UTI symptom assessment questionnaire79 and negative urine culture (\\\u003C103 colony forming units per ml of urine).\n* Able to attend all follow-up appointments for the study.\n* A negative upper and lower urinary tract evaluation, including pelvic examination for pelvic organ prolapse (less than stage 2), measurement of post-void residual (less than 50 ml), and imaging (renal ultrasound and standing voiding cystourethrogram) to exclude kidney stone, hydronephrosis, reflux, or urethral diverticulum.\n\nExclusion Criteria:\n\n* Current use of D-mannose. Patients willing to stop taking D-mannose will be offered to join the trial after a 4-week wash-out period.\n* Complicated UTIs, including need for catheter drainage or intermittent catheterization, neurogenic bladder, bladder augmentation, or urinary diversion.\n* Ongoing supplement use (Box 1). Patients willing to stop taking the listed supplements will be offered to join the trial after a 4-week wash-out period.\n* Evidence of upper tract infection (pyelonephritis), including temperature higher than 38°C, flank\u002Flumbar pain or tenderness\n* Diagnosis of interstitial cystitis or overactive bladder syndrome\n* Prophylactic antibiotics started in the last 3 months and unwilling to discontinue, or intention to start in the next 12 months\n* Use of Uromune or other vaccine approaches to reduce rUTI\n* Participation in a research study involving an investigational product in the past 12 weeks\n* Receipt of phage treatment\n* History of chronic diarrhea requiring regular therapy\n* Inability to swallow or known history of gastrointestinal malabsorption\n* History of recurrent vaginal yeast infections\n* Systemic disease precluding enrollment in this study (uncontrolled diabetes with HgA1C above 7, ongoing chemotherapy or immunotherapy, renal insufficiency \\[creatinine \\> 1.5 g\u002Fdl\\]), mental or cognitive impairment, weight loss diet requiring excessively large amounts of fluid intake, or other health-related specific diet).\n* Nursing home resident\n* BMI \\>40\n\nBox 1 Supplements to avoid\n\n* Multi-Vitamins and Multi-Mineral capsules\n* Specific Vitamins or Minerals (e.g., Calcium, Citrical, Calcium Gummies, Vitamin A, D, Niacin, Pyridoxine, Selenium, Vitamin E, B6, Iron, Omega 3, D3, Magnesium, B-Complex, Women's Ultra MultiVitamin, GNC B-Complex, B-12, PreserVision Areds2, Vitamins D, B Pollen)\n* Probiotics\n* Cranberry Mannose or Cranberry Extract Weight loss products to avoid\n* Medifast\n* Vitafusion\n* OptiVin Products\n* Appetite Suppressants\n* Keto-Fuel","55 Years","85 Years",{"count":93,"type":20},90,[69],"A randomized, double-blind, placebo-controlled, 12-month study to determine the effectiveness of D-mannose (2g daily) supplementation in rUTI (recurrent urinary tract infection) prevention in post-menopausal women.",[97,98,99,100,101,102,60,31,103],"Recurrent UTIs","Recurrent Urinary Tract Infections","Recurrent Urinary Tract Infections in Women","Recurrent Urinary Tract Infection","Cystitis Recurrent","Cystitis Chronic","UTI - Lower Urinary Tract Infection",[105,106,107,108,109,110,111,112,113],"D-mannose","dmannose","uti","ruti","recurrent urinary tract infection","urinary tract infection","cystitis","chronic uti","chronic cystitis","2025-09-18",{"date":116,"type":45},"2025-09-22",{"date":118,"type":45},"2025-08-01",{"date":120,"type":20},"2030-09-30",{"name":122,"class":52},"University of Texas Southwestern Medical Center"]